Nanoscope’s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress

Nanoscope’s  Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress

DALLAS, Dec. 2, 2024  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA) secondary to macular degeneration, today announced that Jordi Monés will provide a presentation of Nanoscope clinical data at the annual FLORetina conference taking place on December 5th-8th at the Fortezza da Basso in Florence Italy. Details for the presentation are as follows:

Title: Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results From a Long-Term Follow-Up Study (REMAIN)

Session Title: Retina Futura, Session 1
Session Date: December 6th, 2024
Session Time: 12:18 pm CEST
Location: San Giovanni room, Fortezza da Basso, Florence
Presenter: Jordi Monés, MD, PhD, Director of Institut de la Màcula, and Barcelona Macula Foundation (Spain)

In addition to observed statistically significant improvements in best corrected visual acuity (BCVA) in Multi-Characteristic Opsin (MCO-010) treated retinitis pigmentosa (RP) patients of RESTORE multicenter, randomized, double-masked, sham-controlled clinical trial, Dr. Monés will present the durable efficacy and safety up to 126-week, observed in the REMAIN long term follow-up study.

About Nanoscope Therapeutics, Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for GA.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

On December 2, 2024   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Dr. Mohanty obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.